ClinicalTrials.gg
Not yet recruitingNCT07556861Updated Jul 31, 2026

Senyo Health App - Comorbid Alcohol Use Disorder Treatment in Individuals With Bipolar Disorder Using a Telehealth Collaborative Care Platform

An interventional study of Senyo Health App in Bipolar Disorder, sponsored by Mayo Clinic. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-07-31.

Sponsored by Mayo Clinic · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
40
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 13 studies in Bipolar Disorder by Mayo Clinic — 5 open to participants now, 6 under way, none of them phase 3. Bipolar Disorder · Mayo Clinic.

Planned enrollment
6th of 12
40 · median 35
Started
2026
with 2 others
No phase
3 of 13
2 open now
Registered
13th of 13
by date

Among the 13 studies in Bipolar Disorder by Mayo Clinic, this one is the 6th largest by planned enrollment of the 12 interventional ones that give a count, is one of 3 that started in 2026, is one of 3 with no phase, and was the 13th registered.

Bipolar Disorder

1,687 studies on the registry are indexed under Bipolar Disorder; 268 are open to participants now.

Browse Bipolar Disorder studies →

Open to participants now

5 of the 13 studies in Bipolar Disorder by Mayo Clinic are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 207 Bipolar Disorder studies recruiting now, 60 (29%) set no upper age limit and 134 (65%) stop at 75 or younger; 38 take children under 18; 51 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Bipolar Disorder by Mayo Clinic, or all of them as a file.
02

Study summary

The purpose of this study is to examine the effectiveness of a digital integrated behavioral health (IBH) platform in improving alcohol use outcomes, including treatment retention and substance use frequency and severity in patients with Bipolar Disorder.

03

Conditions studied

  • Bipolar Disorder

Keywords

  • Bipolar
  • Substance Use
  • SUD
  • Alcohol
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age>=18 years;
  2. History of bipolar I disorder, bipolar II disorder, or schizoaffective disorder of the bipolar type. Can be clinical diagnosis
  3. Ability to read, write, and understand English;
  4. Minimum DAST (1+) or AUDIT-C score (3+)
  5. Access and willingness to use a mobile device for asynchronous (text) and synchronous (video) engagement with care;
  6. Eligibility determined by ASAM Assessment as completed by a LADC.

Exclusion criteria

Exclusion Criteria:

  1. Inability to actively participate in and learn from psychotherapeutic interaction based on clinical evaluation and clinical judgment;
  2. Needing a higher level of mental health care as demonstrated by ASAM[36] assessment; - completed by LADC or MD investigators
  3. Already admitted into or about to initiate treatment in another addiction treatment program.
  4. Currently attending High School. (can be 18 though)
  5. Pregnancy confirmed by self-report
  6. Inability to provide written .
  7. Inability to understand English.
  8. Clinically unstable medical disease.
  9. Otherwise excluded for administrative reasons and/or clinician judgment.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Experimental
    Senyo Health app

    Patients will utilize the Senyo Health app daily, for 12 weeks

    Other: Senyo Health App

Interventions

  • OtherSenyo Health App

    The Senyo Health app includes asynchronous cognitive behavioral therapy (CBT) modules, contingency management, behavioral activation, and an interface to interact with the care manager for support in treating the comorbidities of bipolar disorder and substance use disorder. Patients will engage with the app daily and have weekly check-in visits with the care manager. After the initial 12 week intervention phase, subjects will be followed for 1 year.

06

What researchers measure

Primary outcomes

  1. System Usability Scale (SUS) score

    The System Usability Scale (SUS) is a 10-item scale to assess usability of the app. Statements are rated on a 5 point scale where 1 = 'strongly disagree' and 5 = 'strongly agree'. Higher total scores indicates higher perception of app usability by patients.

    Time frame: 12 weeks

  2. Acceptability of Intervention Measure (AIM)

    The Acceptability of Intervention Measure (AIM) is a 12 question survey that assesses acceptability, appropriateness, and feasibility of the app. Responses are on a 5 point scale where 1 = 'completely disagree' and 5 = 'completely agree'. Higher scores indicate greater acceptance of the app.

    Time frame: 12 weeks

  3. Intervention Appropriatness Measure

    The Intervention Appropriateness Measure (IAM) is a tool consisting of 4 items designed to assess the suitability and relevance of an intervention without specifying a particular purpose, person, or situation. It aims to provide a generalizable assessment of the appropriateness of interventions by capturing individual perspectives on the alignment of the intervention with professional values and perceived efficacy in meeting patient needs.

    Time frame: 12 weeks

  4. Feasibility of Intervention Measure

    Measuring the feasibility or extent to which a new treatment, or an innovation, can be successfully used or carried out within a given agency or setting.

    Time frame: 12 weeks

  5. Timeline Follow Back

    Gather the history of substance use, such as how much you used each day.

    Time frame: Baseline, Weekly for 12 weeks, then monthly for 3 months. 9 months and 1 year.

Secondary outcomes

  1. Change in Brief Substance Craving Scale (BSCS) score

    The Brief Substance Craving Scale (BSCS) survey assesses the intensity, frequency, number of times, and length of time a subject craves a substance over a 24 hour period. The statements are rated on a 5 point scale, where 0 = 'never/none' and 4 = 'extreme/constant'. Higher overall scores indicates a greater deal of craving for substances of abuse.

    Time frame: Baseline, weekly for 12 weeks, 4 months, 5 months, 6 months, 9 months, 12 months

  2. Change in Generalized Anxiety Disorder-7 (GAD-7) score

    The General Anxiety Disorder is a 7-item scale to assess severity of generalized anxiety disorder. Scoring is calculated by assigning scores of 0, 1, 2, and 3 to the response categories, respectively, of 'not at all', 'several days', 'more than half the days', and 'nearly every day'. Total score for the seven items ranges from 0 to 21 where 0 is no anxiety, 1-4 is minimal anxiety, 5-9 is mild anxiety, 10-14 is moderate anxiety, and 15-21 is severe anxiety.

    Time frame: Baseline, weekly for 12 weeks, 4 months, 5 months, 6 months, 9 months, 12 months

  3. Change in Patient Health Questionnaire-9 (PHQ-9) score

    The Patient Health Questionnaire 9-item (PHQ-9) scale is used to assess severity of depression. Scoring is calculated by assigning scores of 0, 1, 2, and 3 to the response categories, respectively, of 'not at all', 'several days', 'more than half the days', and 'nearly every day'. Total score ranges from 0 to 27 where 0 is no depression, 1-4 is minimal depression, 5-9 is mild depression, 10-14 is moderate depression, and 15-19 is moderately severe depression and 20-27 severe depression.

    Time frame: Baseline, weekly for 12 weeks, 4 months, 5 months, 6 months, 9 months, 12 months

  4. Change in Patient Mania Questionnaire-9 (PMQ-9) score

    The Patient Mania Questionnaire-9 (PMQ-9) questionnaire is a 9 item scale to assess symptoms of mania. Statements are rated on a 4 point scale where 0 = 'not at all' and 3 = 'nearly every day'. Higher overall scores indicate a greater presence of mania type symptoms.

    Time frame: Baseline, weekly for 12 weeks, 4 months, 5 months, 6 months, 9 months, 12 months

  5. Change in Brief Assessment of Recovery Capital (BARC-10) score

    The Brief Assessment of Recovery Capital (BARC-10) survey is a 10 item questionnaire used to assess the tools and resources a patient has available to support recovery. Statements are rated on a 6 point scale, where 1 = 'strongly disagree' and 6 = 'strongly agree'. Higher scores indicate a greater level of support available to the patient.

    Time frame: Baseline, 1 month, 2 months, 3 months, 4 months, 5 months, 6 months, 9 months, 1 year

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Sep 2026; primary completion for Jan 2029, 28 months later.

Of 361 non-industry interventional studies with no phase under Bipolar Disorder, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 58. This study's planned 28 months is below that.

Counting every sponsor, half of 363 studies reached it within 37 months; a quarter within 23 and three quarters within 58.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 22, 2026
First posted
Apr 29, 2026
StartEst.
Sep 16, 2026
Primary completionEst.
Jan 20, 2029
CompletionEst.
Jan 20, 2029
Last update
Jul 31, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 31, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07556861
Lead sponsor
Mayo Clinic
Responsible party
Mark Frye (Principal Investigator, Mayo Clinic) — Principal investigator
First posted
Apr 29, 2026
Start date
Sep 16, 2026 (estimated)
Primary completion
Jan 20, 2029 (estimated)
Completion
Jan 20, 2029 (estimated)
Last update
Jul 31, 2026

Study contacts

Kelsey Tuen
Contact
tuen.kelsey@mayo.edu
507-284-2088
Bryce Leatherman
Contact
leatherman.bryce@mayo.edu
5074222079
Mark A. Frye, MD
principal investigator · Mayo Clinic
Tyler S. Oesterle, MD, MPH
principal investigator · Mayo Clinic

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion